Shanghai Life Sciences Partner Quoted in Pink Sheet on China FDA Proposed Rule Changes for New Drug Approvals

In The News
March 28, 2017

Life sciences partner Katherine Wang (Shanghai) is quoted in a March 21 article in The Pink Sheet regarding a China Food and Drug Administration (CFDA) draft regulation that proposes to revise a burdensome requirement relating to the conduct of multi-regional clinical trials (MRCTs) at sites in China, and which will potentially allow simultaneous conduct of early-stage studies in the country.

Ms. Wang notes that the CFDA proposed rule changes would have the positive effects of both helping to obtain clinical trial approvals and easing requirements on new drug applications for imported drugs in China.